Murphy Middleton Hinkle & Parker Inc. Makes New Investment in Danaher Corporation $DHR

Murphy Middleton Hinkle & Parker Inc. bought a new stake in shares of Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 31,526 shares of the conglomerate’s stock, valued at approximately $6,985,000. Danaher comprises about 2.8% of Murphy Middleton Hinkle & Parker Inc.’s investment portfolio, making the stock its 7th largest holding.

Several other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Danaher in the 2nd quarter worth about $10,492,520,000. Wellington Management Group LLP boosted its holdings in shares of Danaher by 10.4% in the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after buying an additional 1,542,310 shares during the period. Jupiter Topco LLC acquired a new position in shares of Danaher in the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP bought a new stake in shares of Danaher during the 2nd quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE bought a new stake in shares of Danaher during the 2nd quarter valued at about $993,846,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

DHR stock opened at $231.52 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock has a market capitalization of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock’s fifty day moving average is $213.55 and its two-hundred day moving average is $195.74.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.77 earnings per share. On average, research analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DHR. Royal Bank Of Canada increased their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Evercore reissued an “outperform” rating and issued a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Morgan Stanley lifted their target price on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday. The Goldman Sachs Group upped their target price on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Finally, TD Cowen upped their target price on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.